Hematology

Approximately 41% of enrolled patients responded to NX-2127, and the BTK degrader overcame resistance to nearly all BTK mutations that were identified to cause resistance.

According to the authors, the test has promise in guiding treatment but needs further refining to obtain information beyond molecular subtyping.

The findings suggest that further research on additional intervention methods and expanding access to hydroxyurea in Africa could benefit young patients with sickle cell disease.

Less manufacturing time could be the difference between a patient receiving this life-saving therapy vs not.

Pharmacy Times provides a comprehensive recap of the latest advancements in hematology and breast cancer, shared at the 2023 American Society of Hematology and the San Antonio Breast Cancer Symposium conferences

The MRD-guided treatment approach has a significant advantage over chemotherapy.

It can also help identify patients who would benefit from disease-specific therapies.

Data support the quadruplet regimen as a new standard of care for transplant-eligible patients.

There is a significant efficacy-effectiveness gap in standard-of-care regimens.

Further policy changes to promote gender equity may be needed.

Kyle Farina, PharmD, BCPS, BCOP, addresses the multifaceted role of pharmacists in CLL management, including their role in patient care, treatment decision support, and addressing safety considerations.

PTX-252 is a novel molecular drug designed to increase cancer cells' sensitivity to chemotherapy in the treatment of acute myeloid leukemia.

Presentations detail clinical trial results and focus on drugs in the pipeline.

2023 was an impactful year for the field of oncology pharmacy.

Not only were individuals with BMIs of 30 and higher likely to have MGUS, but those who reported heavy smoking and short sleep were also more likely to have detectable levels of MGUS.

A leukemia clinical pharmacy specialist delves into the significance of educating patients on treatments and serving as a resource for both patients and health care providers.

In addition, patients who were treated with liso-cel therapy had a higher average life expectancy and QALYs, compared to those who were treated with standard care.

Compared to standard of care TKIs, asciminib also presented favorable safety and tolerability profiles with fewer reported AEs among patients.

The study results also demonstrated isatuximab had safety and tolerability profiles that were consistent with other clinical trials.

Nearly 75% of patients who had an initial complete response with mosunetuzumab maintained that complete response after 3 years.

Eliminating certain factors within the GRN resulted in the network shutting down, potentially leading to cancer cell death due to an inability to replicate, according to the study authors.

New CAR T development method infuses immune T cells from healthy people into patients to improve outcomes.

The investigators advise that the use of bendamustine should be avoided when possible in patients with refractory LBCL who are potential candidates for CAR T-cell therapy.

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.